XML 39 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements and Derivative Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2016
Fair Value Disclosures [Abstract]  
Financial Liabilities Measured at Fair Value on Recurring Basis

The following table presents the Company’s financial liabilities measured at fair value on a recurring basis as of September 30, 2016 and December 31, 2015, at each hierarchical level:

 

     September 30, 2016      December 31, 2015  
     Total     Level 1      Level 2     Level 3      Total     Level 1      Level 2     Level 3  

Other long-term liabilities:

                   

Interest rate swaps

   $ (147   $ —         $ (147   $ —         $ (79   $ —         $ (79   $ —     
Schedule of Derivative Financial Instruments Designated as Cash Flow Hedges

The following table presents the notional amount, fair value and balance sheet classification of the Company’s derivative financial instruments designated as cash flow hedges as of September 30, 2016 and December, 31, 2015:

 

     Balance Sheet Location      Notional
Amount
     Fair
Value
 
At September 30, 2016:         

Interest rate swaps

     Other long-term liabilities       $ 43,269       $ 147   
At December 31, 2015:         

Interest rate swaps

     Other long-term liabilities       $ 44,827       $ 79   
Schedule of Gains and Losses Before Income Taxes Recognized on Interest Rate Swaps Designated as Cash Flow Hedges

The following table presents gains and losses before income taxes on the Company’s interest rate swaps designated as cash flow hedges for the three and nine-month periods ending September 30, 2016 and 2015:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

(Loss) gain recognized in accumulated other comprehensive loss

   $ (6    $ 199       $ (180    $ 596   

(Loss) gain reclassified from accumulated other comprehensive loss (effective portion)

     (27      —           (80      1,970   

Gain recognized in interest expense (ineffective portion and amount excluded from effectiveness testing)

     —           279         —           820